Table 1.
Baseline patient characteristics in the per-protocol analysis of enrolled patients (n = 202).
| Age, Years, Mean (SD) | 71.1 (13.9) |
| Sex, % (n) | |
| Male | 51.5 (104) |
| Female | 48.5 (98) |
| ECOG PS, % (n) | |
| 0 | 35.6 (72) |
| 1 | 30.7 (62) |
| 2 | 16.8 (34) |
| 3 | 13.9 (28) |
| 4 | 3.0 (6) |
| ASA-PS classification, % (n) | |
| 1 | 44.6 (90) |
| 2 | 39.1 (79) |
| 3 | 14.9 (30) |
| 4 | 1.5 (3) |
| Any symptoms of obstruction, % (n) | 95.5 (193) |
| Deterioration of bowel habit | 91.6 (185) |
| Bloating | 80.7 (163) |
| Abdominal pain/cramp | 75.7 (153) |
| Nausea or vomiting | 46.0 (93) |
| CROSS before stent placement, % (n) | |
| 0 | 34.2 (69) |
| 1 | 26.2 (53) |
| 2 | 17.8 (36) |
| 3 | 18.3 (37) |
| 4 | 3.5 (7) |
| Etiology of colorectal obstruction, % (n) | |
| Primary colorectal cancer | 85.6 (173) |
| Locally recurrent colorectal cancer | 1.0 (2) |
| Other extrinsic origin | 12.9 (26) |
| Benign ulcer | 0.5 (1) |
| Underlying disease, % (n) | |
| Only local cancer | 55.9 (113) |
| Cancer with distant metastases | 43.6 (88) |
| Liver metastasis | 21.8 (44) |
| Lung metastasis | 10.9 (22) |
| Peritoneal carcinomatosis | 20.8 (42) |
| Other metastases | 18.3 (37) |
| Benign lesion, % (n) | 0.5 (1) |
| Treatment history, % (n) | |
| Chemotherapy | 13.9 (28) |
| Radiotherapy | 1.0 (2) |
| Stricture balloon dilation | 0 (0) |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; ASA-PS, American Society of Anesthesiologists Physical Status; CROSS, ColoRectal Obstruction Scoring System.